- Home
- ARTW vs GLTO Comparison
ARTW vs GLTO Comparison
Compare ARTW & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTW
- GLTO
- Stock Information
- Founded
- ARTW 1956
- GLTO 2011
- Country
- ARTW United States
- GLTO Denmark
- Employees
- ARTW N/A
- GLTO N/A
- Industry
- ARTW Industrial Machinery/Components
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ARTW Industrials
- GLTO Health Care
- Exchange
- ARTW Nasdaq
- GLTO Nasdaq
- Market Cap
- ARTW 8.0M
- GLTO 6.5M
- IPO Year
- ARTW N/A
- GLTO 2020
- Fundamental
- Price
- ARTW $1.50
- GLTO $2.65
- Analyst Decision
- ARTW
- GLTO Buy
- Analyst Count
- ARTW 0
- GLTO 1
- Target Price
- ARTW N/A
- GLTO $10.00
- AVG Volume (30 Days)
- ARTW 33.5K
- GLTO 50.2K
- Earning Date
- ARTW 04-09-2025
- GLTO 04-28-2025
- Dividend Yield
- ARTW N/A
- GLTO N/A
- EPS Growth
- ARTW N/A
- GLTO N/A
- EPS
- ARTW 0.14
- GLTO N/A
- Revenue
- ARTW $23,916,932.00
- GLTO N/A
- Revenue This Year
- ARTW N/A
- GLTO N/A
- Revenue Next Year
- ARTW N/A
- GLTO N/A
- P/E Ratio
- ARTW $31.75
- GLTO N/A
- Revenue Growth
- ARTW N/A
- GLTO N/A
- 52 Week Low
- ARTW $1.33
- GLTO $2.01
- 52 Week High
- ARTW $4.15
- GLTO $18.50
- Technical
- Relative Strength Index (RSI)
- ARTW 48.25
- GLTO 44.50
- Support Level
- ARTW $1.48
- GLTO $2.36
- Resistance Level
- ARTW $1.67
- GLTO $2.63
- Average True Range (ATR)
- ARTW 0.10
- GLTO 0.30
- MACD
- ARTW 0.01
- GLTO 0.06
- Stochastic Oscillator
- ARTW 56.00
- GLTO 66.07
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.